Synthon's success in the field of complex generic medicines has been a stimulus for us to start development of our own biopharmaceuticals in 2007. The ambition of our biopharmaceutical business is to be best-in-class or first-in-class with innovative products based on new biological and new chemical entities. Our growing portfolio reflects our focus and commitment to bringing medicines to patients with a high unmet medical need, notably in oncology and autoimmune diseases.
As part of the Synthon Group, Synthon Biopharmaceuticals is well-positioned to build on the success, global infrastructure and organization of the financially strong, privately held parent company. This distinguishes our innovative Biopharmaceuticals business from other biotech companies and also allows us to make creative choices and to be flexible and dynamic.
We have built state-of-the-art biopharmaceutical research laboratories and GMP facilities for manufacturing monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) - up to Phase III clinical trials and early launches - both for our own portfolio and also to support commercial licensees of our ADC technology.
Our investment in infrastructure and technology is matched by our investment in people. Since the inception of our innovative business we have gradually built an organization that comprises all the expertise necessary to bring innovative drug candidates to the market.
We offer selected external parties access to our linker-drug and conjugation technology and (GMP) manufacturing capabilities for (site-specific) conjugation of their own proprietary monoclonal antibodies.
CHI’s Inaugural CMC Strategies for Antibody-Drug Conjugates invites scientists to share their expertise in the areas of regulatory affairs, analytics,…read more
The Optimizing Cell Line Development conference brings together cell line development experts who share real-world strategies for quickly achieving…read more